Literature DB >> 18824499

Long-term outcome prediction by clinicopathological risk classification algorithms in node-negative breast cancer--comparison between Adjuvant!, St Gallen, and a novel risk algorithm used in the prospective randomized Node-Negative-Breast Cancer-3 (NNBC-3) trial.

M Schmidt1, A Victor, D Bratzel, D Boehm, C Cotarelo, A Lebrecht, W Siggelkow, J G Hengstler, A Elsässer, M Gehrmann, H-A Lehr, H Koelbl, G von Minckwitz, N Harbeck, C Thomssen.   

Abstract

BACKGROUND: Defining risk categories in breast cancer is of considerable clinical significance. We have developed a novel risk classification algorithm and compared its prognostic utility to the Web-based tool Adjuvant! and to the St Gallen risk classification. PATIENTS AND METHODS: After a median follow-up of 10 years, we retrospectively analyzed 410 consecutive node-negative breast cancer patients who had not received adjuvant systemic therapy. High risk was defined by any of the following criteria: (i) age <35 years, (ii) grade 3, (iii) human epithelial growth factor receptor-2 positivity, (iv) vascular invasion, (v) progesterone receptor negativity, (vi) grade 2 tumors >2 cm. All patients were also characterized using Adjuvant! and the St Gallen 2007 risk categories. We analyzed disease-free survival (DFS) and overall survival (OS).
RESULTS: The Node-Negative-Breast Cancer-3 (NNBC-3) algorithm enlarged the low-risk group to 37% as compared with Adjuvant! (17%) and St Gallen (18%), respectively. In multivariate analysis, both Adjuvant! [P = 0.027, hazard ratio (HR) 3.81, 96% confidence interval (CI) 1.16-12.47] and the NNBC-3 risk classification (P = 0.049, HR 1.95, 95% CI 1.00-3.81) significantly predicted OS, but only the NNBC-3 algorithm retained its prognostic significance in multivariate analysis for DFS (P < 0.0005).
CONCLUSION: The novel NNBC-3 risk algorithm is the only clinicopathological risk classification algorithm significantly predicting DFS as well as OS.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18824499     DOI: 10.1093/annonc/mdn590

Source DB:  PubMed          Journal:  Ann Oncol        ISSN: 0923-7534            Impact factor:   32.976


  35 in total

1.  Node-Negative Breast Cancer: Which Patients Should Be Treated?

Authors:  Marcus Schmidt
Journal:  Breast Care (Basel)       Date:  2008-08-20       Impact factor: 2.860

2.  Post-operative nomogram for predicting freedom from recurrence after surgery in localised breast cancer receiving adjuvant hormone therapy.

Authors:  Chafika Mazouni; Frédéric Fina; Sylvie Romain; Pascal Bonnier; L'houcine Ouafik; Pierre-Marie Martin
Journal:  J Cancer Res Clin Oncol       Date:  2014-11-30       Impact factor: 4.553

3.  Limited influence of germline genetic variation on all-cause mortality in women with early onset breast cancer: evidence from gene-based tests, single-marker regression, and whole-genome prediction.

Authors:  Molly Scannell Bryan; Maria Argos; Irene L Andrulis; John L Hopper; Jenny Chang-Claude; Kathleen Malone; Esther M John; Marilie D Gammon; Mary Daly; Mary Beth Terry; Saundra S Buys; Dezheng Huo; Olofunmilayo Olopade; Jeanine M Genkinger; Farzana Jasmine; Muhammad G Kibriya; Lin Chen; Habibul Ahsan
Journal:  Breast Cancer Res Treat       Date:  2017-05-13       Impact factor: 4.872

4.  The histone chaperone HJURP is a new independent prognostic marker for luminal A breast carcinoma.

Authors:  Rocío Montes de Oca; Zachary A Gurard-Levin; Frédérique Berger; Haniya Rehman; Elise Martel; Armelle Corpet; Leanne de Koning; Isabelle Vassias; Laurence O W Wilson; Didier Meseure; Fabien Reyal; Alexia Savignoni; Bernard Asselain; Xavier Sastre-Garau; Geneviève Almouzni
Journal:  Mol Oncol       Date:  2014-11-20       Impact factor: 6.603

5.  Comparison of scores for bimodality of gene expression distributions and genome-wide evaluation of the prognostic relevance of high-scoring genes.

Authors:  Birte Hellwig; Jan G Hengstler; Marcus Schmidt; Mathias C Gehrmann; Wiebke Schormann; Jörg Rahnenführer
Journal:  BMC Bioinformatics       Date:  2010-05-25       Impact factor: 3.169

6.  Use of ER/PR/HER2 subtypes in conjunction with the 2007 St Gallen Consensus Statement for early breast cancer.

Authors:  Katrina Bauer; Carol Parise; Vincent Caggiano
Journal:  BMC Cancer       Date:  2010-05-21       Impact factor: 4.430

7.  Role of thioredoxin reductase 1 and thioredoxin interacting protein in prognosis of breast cancer.

Authors:  Cristina Cadenas; Dennis Franckenstein; Marcus Schmidt; Mathias Gehrmann; Matthias Hermes; Bettina Geppert; Wiebke Schormann; Lindsey J Maccoux; Markus Schug; Anika Schumann; Christian Wilhelm; Evgenia Freis; Katja Ickstadt; Jörg Rahnenführer; Jörg I Baumbach; Albert Sickmann; Jan G Hengstler
Journal:  Breast Cancer Res       Date:  2010-06-28       Impact factor: 6.466

Review 8.  Breast cancer classification and prognostication through diverse systems along with recent emerging findings in this respect; the dawn of new perspectives in the clinical applications.

Authors:  Vida Pourteimoor; Samira Mohammadi-Yeganeh; Mahdi Paryan
Journal:  Tumour Biol       Date:  2016-09-20

Review 9.  Chemotherapy in early breast cancer: when, how and which one?

Authors:  Marcus Schmidt
Journal:  Breast Care (Basel)       Date:  2014-07       Impact factor: 2.860

10.  An investigation into the performance of the Adjuvant! Online prognostic programme in early breast cancer for a cohort of patients in the United Kingdom.

Authors:  H E Campbell; M A Taylor; A L Harris; A M Gray
Journal:  Br J Cancer       Date:  2009-09-01       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.